Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -40

Novo Nordisk sued by shareholders over weight-loss drug: What to know

🏛️ A federal judge ruled that parts of a shareholder lawsuit against Novo Nordisk can proceed, finding plausible allegations that statements about CagriSema's tolerability and trial design were misleading.

💊 The lawsuit centers on the December 2024 release of CagriSema results showing 20.4% average weight loss versus the expected 25%, which caused Novo's stock to drop sharply.

📉 Investors allege Novo misrepresented the REDEFINE-1 trial as having a fixed-dose approach when it actually used flexible dosing, with only 57% of participants reaching the maximum level.

⚖️ Judge Robert Kirsch allowed claims involving former executive Martin Holst Lange to continue, noting he was presented to investors as a key authority on clinical trial design.

🛡️ Novo Nordisk spokespersons stated the company believes the allegations are meritless and plans to vigorously defend against them in the upcoming discovery phase.

📊 Following the disappointing CagriSema data, Novo's American depositary receipts fell $18.15 per share (17.83%) with over 53 million shares traded in a single day.

🚀 The legal battle highlights Novo's strategic reliance on its obesity pipeline, including CagriSema and higher-dose Wegovy, to counter growing competition from Eli Lilly.

📝 The ruling does not determine if fraud occurred but establishes that specific claims regarding trial protocols meet the legal threshold for further investigation.

⚡ This shareholder case is separate from Novo's recent lawsuit against Eli Lilly, which concerns unfair advertising comparisons rather than internal clinical trial disclosures.

Bullish Signals
  • Novo Nordisk intends to vigorously defend against the shareholder allegations, asserting that the claims are meritless and denying any wrongdoing regarding CagriSema.
  • The company continues to push forward with its obesity pipeline strategy, counting on CagriSema, higher-dose Wegovy, and oral versions of its medicines to strengthen its market position against competitors like Eli Lilly.
Risk Factors
  • A federal judge allowed claims that Novo Nordisk misled investors about CagriSema's tolerability and trial design to proceed, potentially exposing the company to significant financial liability if securities fraud is proven.
  • The REDEFINE-1 study utilized a flexible dosing approach where only 57% of participants reached the highest dose, contradicting investor expectations of a fixed-dose regimen similar to earlier trials.
  • Following the release of CagriSema results, Novo's American depositary receipts dropped $18.15 per share (17.83%) with over 53 million shares traded, wiping billions off its market value.
  • Former executive Martin Holst Lange faces specific allegations that his comments about the drug's tolerability profile and dosing approach were misleading to investors.
Full Analysis
A federal judge has allowed parts of a shareholder lawsuit against Novo Nordisk to proceed, alleging the company misled investors regarding its experimental weight-loss drug, CagriSema. The core dispute involves claims that Novo presented misleading information about the clinical trial design and tolerability of CagriSema before releasing disappointing December 2024 results that caused billions in market value loss. The lawsuit specifically targets statements suggesting a fixed-dose approach similar to earlier trials, whereas the REDEFINE-1 study utilized a flexible dosing method where only 57% of participants reached the highest dose. Judge Robert Kirsch ruled that while many allegations were rejected, claims concerning drug tolerability and specific comments by former executive Martin Holst Lange meet the legal standard to move forward into discovery. Novo Nordisk denies wrongdoing and intends to vigorously defend against the charges, stating the allegations are meritless. This legal development occurs as the Danish pharmaceutical giant faces intense competition from Eli Lilly and relies heavily on its obesity pipeline, including CagriSema, higher-dose Wegovy, and oral treatments, to maintain market share and investor confidence. Following the December announcement of CagriSema results, Novo's American depositary receipts dropped 17.83% with over 53 million shares traded, while Copenhagen-listed shares fell 20.7%. The case is distinct from a separate lawsuit Novo filed against Eli Lilly regarding advertising comparisons, focusing instead on securities law violations related to investor disclosures about clinical trial protocols.